Vir Biotechnology, Inc. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Vir Biotechnology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2026-06-30 was $0.00.
- Vir Biotechnology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2026-03-31 was $0.00.
- Vir Biotechnology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2025-12-31 was $0.00.
- Vir Biotechnology, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2025-09-30 was $0.00.
- Vir Biotechnology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Vir Biotechnology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2024 was $1.00K.
- Vir Biotechnology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2020 was $1.44M, a 201.47% increase from fiscal 2019.
- Vir Biotechnology, Inc. stock issued during period, value, restricted stock award, gross for fiscal 2019 was $476.00K.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-06-30 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-02-23 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $1.00K 10-Q · filed 2025-05-08 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | |
| 2020-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.44M 10-K · filed 2023-02-28 |
| 2020-09-30 | $427.00K 10-Q · filed 2021-11-04 | $1.67M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $462.00K 10-Q · filed 2021-08-05 | $1.36M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $427.00K 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $476.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $119.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |